milrinone has been researched along with Prostatic Hyperplasia in 1 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drescher, P | 1 |
| Eckert, RE | 1 |
| Madsen, PO | 1 |
1 other study available for milrinone and Prostatic Hyperplasia
| Article | Year |
|---|---|
Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate.
Topics: Bucladesine; Colforsin; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Male; Milrinone; Muscl | 1994 |